[HTML][HTML] Brodalumab, an anti-IL17RA monoclonal antibody, in psoriatic arthritis

PJ Mease, MC Genovese, MW Greenwald… - … England Journal of …, 2014 - Mass Medical Soc
PJ Mease, MC Genovese, MW Greenwald, CT Ritchlin, AD Beaulieu, A Deodhar
New England Journal of Medicine, 2014Mass Medical Soc
Background We assessed the efficacy and safety of brodalumab, a human monoclonal
antibody against interleukin-17 receptor A (IL17RA), in a phase 2, randomized, double-
blind, placebo-controlled study involving patients with psoriatic arthritis. Methods We
randomly assigned patients with active psoriatic arthritis to receive brodalumab (140 or 280
mg subcutaneously) or placebo on day 1 and at weeks 1, 2, 4, 6, 8, and 10. At week 12,
patients who had not discontinued their participation in the study were offered open-label …
Background
We assessed the efficacy and safety of brodalumab, a human monoclonal antibody against interleukin-17 receptor A (IL17RA), in a phase 2, randomized, double-blind, placebo-controlled study involving patients with psoriatic arthritis.
Methods
We randomly assigned patients with active psoriatic arthritis to receive brodalumab (140 or 280 mg subcutaneously) or placebo on day 1 and at weeks 1, 2, 4, 6, 8, and 10. At week 12, patients who had not discontinued their participation in the study were offered open-label brodalumab (280 mg) every 2 weeks. The primary end point was 20% improvement in American College of Rheumatology response criteria (ACR 20) at week 12.
Results
Of the 168 patients who underwent randomization (57 in the brodalumab 140-mg group, 56 in the brodalumab 280-mg group, and 55 in the placebo group), 159 completed the double-blind phase and 134 completed 40 weeks of the open-label extension. At week 12, the brodalumab 140-mg and 280-mg groups had higher rates of ACR 20 than the placebo group (37% [P=0.03] and 39% [P=0.02], respectively, vs. 18%); they also had higher rates of 50% improvement (ACR 50) (14% [P=0.05] and 14% [P=0.05] vs. 4%). Rates of 70% improvement were not significantly higher in the brodalumab groups. Similar degrees of improvement were noted among patients who had received previous biologic therapy and those who had not received such therapy. At week 24, ACR 20 response rates in the brodalumab 140-mg and 280-mg groups were 51% and 64%, respectively, as compared with 44% among patients who switched from placebo to open-label brodalumab; responses were sustained through week 52. At week 12, serious adverse events had occurred in 3% of patients in the brodalumab groups and in 2% of those in the placebo group.
Conclusions
Brodalumab significantly improved response rates among patients with psoriatic arthritis. Larger studies of longer duration are necessary to assess adverse events. (Funded by Amgen; ClinicalTrials.gov number, NCT01516957.)
The New England Journal Of Medicine